M. Fuerst

A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors.

S. Sahasrabudhe, G. Weiss, D. V. Hoff, 2010 .

More Than a Handful of PARP Inhibitors in Development to Treat Hereditary Breast Cancer

M. Fuerst, 2014 .

Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.

A. Tolcher, K. Papadopoulos, S. Crippa, 2010 .